Curson D A, Barnes T R, Bamber R W, Platt S D, Hirsch S R, Duffy J C
Br J Psychiatry. 1985 May;146:464-9. doi: 10.1192/bjp.146.5.464.
A follow-up study of all patients entering the MRC double-blind trial of fluphenazine decanoate in chronic schizophrenic out-patients achieved a trace rate of 94%. In general, these patients were severely disabled, continued under the care of the maintenance clinic, and their diagnoses remained remarkably consistent; more than one-fifth were found to be in acute schizophrenic relapse and in over a half of these cases, the relapse was not known to the treatment agency. The maintenance clinic attenders were little different from those who no longer used such a facility.
对所有参与医学研究委员会(MRC)癸酸氟奋乃静治疗慢性精神分裂症门诊患者双盲试验的患者进行的一项随访研究,追踪率达到了94%。总体而言,这些患者严重残疾,继续在维持治疗诊所接受护理,并且他们的诊断结果保持高度一致;超过五分之一的患者出现急性精神分裂症复发,其中一半以上的复发情况治疗机构并不知晓。在维持治疗诊所就诊的患者与那些不再使用该机构服务的患者没有太大差别。